Condition (MeSH)
Atrophic Vaginitis
ClinicalTrials.gov lists 44 trials for Atrophic Vaginitis or a narrower condition beneath it. EndoCeutics Inc. has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
44 of the 44 trials are tagged with Atrophic Vaginitis itself; the rest are tagged with a narrower condition beneath it.
When did Atrophic Vaginitis trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 5 |
| 2018 | 2 |
| 2017 | 1 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 33 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 28 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Atrophic Vaginitis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 12 |
| Phase 4 | 8 |
| Not applicable | 12 |
| Observational | 2 |
How many Atrophic Vaginitis trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 29 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Atrophic Vaginitis trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| EndoCeutics Inc. | 6 |
| Stratpharma AG | 4 |
| Herbarium Laboratorio Botanico Ltda | 2 |
| Wyeth is now a wholly owned subsidiary of Pfizer | 2 |
| Actavis Inc. | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Atrophic Vaginitis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DHEA | 6 |
| Estriol | 4 |
| PREMARIN | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| [PRP] platelet rich plasma | 2 |
| Conjugated Estrogens vaginal cream 0,625mg | 1 |
| Conjugated Estrogens Cream | 1 |
| Vaginal Moisturizer - Cream | 1 |
| Estrace® Vaginal Cream USP, 0.01% | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Atrophic Vaginitis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Osteoarthritis | 2 | 1 |
| Pancreatitis | 2 | 2 |
| Pulmonary embolism | 2 | 2 |
| Angioedema | 1 | 1 |
| Anxiety | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Atrophic Vaginitis? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A novel objective evaluation method, shear wave elastography, in the treatment of atrophic vaginitis by nonablative intravaginal Er:YAG laser, a randomized-sham controlled pilot study. | Menopause (New York, N.Y.) | 2024 | Yes |
| Comparison of the effect of hyaluronic acid and estrogen on atrophic vaginitis in menopausal women: A systematic review. | Post reproductive health | 2019 | Yes |
| 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. | Menopause (New York, N.Y.) | 2018 | Yes |
| Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. | Mayo Clinic proceedings | 2017 | Yes |
| Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. | American journal of obstetrics and gynecology | 2016 | Yes |
Showing 5 of 15 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.